Profile data is unavailable for this security.
About the company
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
- Revenue in JPY (TTM)0.00
- Net income in JPY-1.87bn
- Incorporated2016
- Employees37.00
- LocationModalis Therapeutics Corp4FY's Bldg., 16-5, Nihonbashi Kabuto-choCHUO-KU 103-0023JapanJPN
- Phone+81 368224584
- Websitehttps://www.modalistx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kidswell Bio Corp | 3.60bn | -883.62m | 4.63bn | 42.00 | -- | 5.41 | -- | 1.29 | -22.78 | -22.78 | 92.26 | 21.08 | 0.9182 | 2.73 | 6.63 | 85,697,070.00 | -22.54 | -57.41 | -35.96 | -81.13 | 36.17 | 55.20 | -24.55 | -123.52 | 1.64 | -17.95 | 0.7132 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
| DNA Chip Research Inc | 766.32m | -118.13m | 4.73bn | 37.00 | -- | 6.74 | -- | 6.17 | -18.29 | -18.29 | 116.80 | 103.64 | 0.9159 | 8.50 | 7.86 | 20,711,350.00 | -14.12 | -23.49 | -17.74 | -26.70 | 38.52 | 14.28 | -15.41 | -54.10 | 2.78 | -641.51 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
| Carna Biosciences, Inc. | 1.40bn | -1.51bn | 5.52bn | 67.00 | -- | 1.96 | -- | 3.94 | -85.98 | -85.98 | 80.34 | 147.09 | 0.391 | 1.19 | 13.59 | 20,922,580.00 | -42.15 | -14.45 | -45.45 | -16.95 | 87.53 | 90.59 | -107.80 | -35.42 | 11.11 | -- | 0.0215 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Veritas In Silico Inc | 246.24m | -148.31m | 5.85bn | 15.00 | -- | 2.54 | -- | 23.76 | -23.92 | -23.92 | 38.93 | 354.61 | 0.1227 | -- | -- | 16,415,930.00 | -7.39 | -- | -7.65 | -- | -- | -- | -60.23 | -- | 67.03 | -- | -- | -- | 101.54 | -- | 123.38 | -- | -- | -- |
| Kringle Pharma Inc | 80.04m | -756.45m | 6.00bn | 13.00 | -- | 2.85 | -- | 74.97 | -118.21 | -118.21 | 12.71 | 309.55 | 0.0298 | -- | 1.15 | -- | -28.14 | -19.17 | -30.03 | -20.40 | -- | -- | -945.12 | -181.86 | 19.20 | -- | -- | -- | 15.58 | -- | 11.44 | -- | -- | -- |
| Chiome Bioscience Inc | 581.07m | -1.22bn | 6.24bn | 51.00 | -- | 5.04 | -- | 10.75 | -22.07 | -22.07 | 10.53 | 19.85 | 0.3371 | 5.16 | 8.01 | 11,393,550.00 | -70.61 | -50.50 | -95.97 | -57.38 | 53.55 | 57.53 | -209.45 | -224.74 | 3.57 | -894.37 | 0.1995 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
| Noile-Immune Biotech Inc | 8.12m | -1.07bn | 7.01bn | 28.00 | -- | 1.43 | -- | 864.12 | -24.64 | -24.64 | 0.1875 | 113.23 | 0.0015 | 0.0229 | 0.0283 | 289,928.60 | -19.15 | -- | -19.61 | -- | 95.58 | -- | -13,139.53 | -- | 79.60 | -- | -- | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| OncoTherapy Science, Inc. | 478.75m | -1.12bn | 8.42bn | 54.00 | -- | 8.42 | -- | 17.59 | -4.86 | -4.86 | 2.04 | 3.68 | 0.3526 | 4.34 | 9.77 | 8,865,722.00 | -82.71 | -55.67 | -106.53 | -63.82 | -32.12 | -1.49 | -234.61 | -247.47 | 3.11 | -- | 0.0731 | -- | -46.24 | 16.81 | -15.15 | -- | -48.33 | -- |
| TMS Co Ltd | 0.00 | -1.10bn | 8.47bn | 14.00 | -- | 2.83 | -- | -- | -28.37 | -28.37 | 0.00 | 74.10 | 0.00 | -- | -- | 0.00 | -33.57 | -- | -34.42 | -- | -- | -- | -- | -- | 31.13 | -- | 0.00 | -- | -- | -- | -11.51 | -- | -- | -- |
| Linical Co Ltd | 11.67bn | -121.16m | 8.51bn | 662.00 | -- | 1.05 | 20.71 | 0.7293 | -5.36 | -5.36 | 516.67 | 326.90 | 0.6575 | -- | 3.74 | 17,628,030.00 | -0.6826 | 4.01 | -1.18 | 6.33 | 26.63 | 30.99 | -1.04 | 5.48 | -- | 2.65 | 0.2588 | 50.81 | -1.67 | 1.70 | -66.32 | -9.86 | -10.18 | 4.56 |
| Modalis Therapeutics Corp | 0.00 | -1.87bn | 9.09bn | 37.00 | -- | 2.95 | -- | -- | -52.79 | -52.79 | 0.00 | 44.35 | 0.00 | -- | -- | 0.00 | -74.95 | -29.19 | -78.46 | -30.02 | -- | -- | -- | -597.35 | 43.87 | -87.46 | 0.0771 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
| Medinet Co Ltd | 768.50m | -1.28bn | 10.58bn | 98.00 | -- | 2.04 | -- | 13.77 | -5.04 | -5.04 | 3.05 | 19.62 | 0.1356 | 11.15 | 3.46 | -- | -22.53 | -21.15 | -23.83 | -22.39 | 14.66 | 22.97 | -166.17 | -160.19 | 18.45 | -- | 0.0002 | -- | 16.17 | -6.21 | 11.19 | -- | -11.16 | -- |
| Tsubota Laboratory Inc | 1.11bn | -303.08m | 10.87bn | 7.00 | -- | 7.70 | -- | 9.78 | -12.09 | -12.09 | 43.15 | 55.21 | 0.4899 | 1.60 | 5.16 | 158,704,300.00 | -13.37 | -- | -18.33 | -- | 52.59 | -- | -27.28 | -- | 2.57 | -24.64 | 0.0678 | -- | -29.45 | -- | -811.14 | -- | -- | -- |
| 3-D Matrix Ltd | 5.25bn | -1.05bn | 11.06bn | 106.00 | -- | 9.52 | -- | 2.11 | -12.89 | -12.89 | 66.88 | 11.66 | 0.8559 | 0.551 | 5.40 | 49,502,420.00 | -17.15 | -42.10 | -21.31 | -55.60 | 68.38 | 53.95 | -20.04 | -96.03 | 2.51 | -- | 0.7979 | -- | 98.30 | 69.41 | 89.55 | -- | -30.34 | -- |
| PRISM BioLab Co Ltd | -100.00bn | -100.00bn | 11.65bn | 22.00 | -- | 5.51 | -- | -- | -- | -- | -- | 58.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -79.63 | -- | -822.18 | -- | -- | -- |
| Nano Mrna Co Ltd | 52.10m | -821.00m | 11.65bn | 18.00 | -- | 3.81 | -- | 223.67 | -11.66 | -11.66 | 0.74 | 43.30 | 0.0102 | 7.01 | 1.56 | 2,894,445.00 | -16.13 | -24.16 | -17.89 | -25.17 | 80.72 | 84.69 | -1,575.81 | -600.70 | 8.17 | -- | 0.2662 | -- | -32.98 | -22.88 | 40.50 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Modalis Therapeutics Corp's reporting currency: Japanese Yen JPY
2.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rheos Capital Works, Inc. (Investment Management)as of 25 Apr 2023 | 1.40m | 2.01% |
| Evolution Capital Management LLCas of 29 Oct 2024 | 254.10k | 0.37% |
| Nikko Asset Management Co., Ltd.as of 27 Sep 2023 | 204.60k | 0.30% |
| JPMorgan Asset Management (Japan) Ltd.as of 25 Apr 2023 | 0.00 | 0.00% |
| Chibagin Asset Management Co. Ltd.as of 30 May 2023 | 0.00 | 0.00% |
More ▼
Data from 11 Mar 2024 - 05 Nov 2024Source: FactSet Research Systems Inc.
